Carnyx Therapeutics Takes Major Step Towards IND Development for CNYX-005, Their Promising Sleep Drug

Carnyx Therapeutics' Milestone in Sleep Disorder Treatment

Carnyx Therapeutics Ltd., a biopharmaceutical firm in the preclinical stage, recently achieved a significant milestone by advancing its primary oral sleep candidate, CNYX-005, into the Investigational New Drug (IND)-enabling development phase. This progress represents a critical step towards conducting first-in-human clinical studies, which could revolutionize treatment options for individuals suffering from sleep disorders.

The Significance of CNYX-005

Why is CNYX-005 drawing attention in the biopharmaceutical realm? Preliminary research indicates that this drug has the potential to notably enhance total sleep duration. Studies conducted on aged rats revealed that CNYX-005 could extend sleep time by approximately 1.5 to 2 hours when compared to control groups. The increase in non-rapid eye movement (NREM) sleep was a striking finding, as NREM sleep is crucial for various cognitive functions, including memory consolidation.

Dr. Chris Brearley, the Chief Medical Officer at Carnyx, expressed optimism regarding CNYX-005's ability to improve not just sleep duration but also the overall quality of sleep. He noted, “The increase in NREM sleep we observed in our preclinical research is encouraging as we further investigate CNYX-005's potential.”

Addressing an Urgent Need

The global market for sleep-disorder treatment is on the verge of rapid expansion, expected to double in value and reach approximately $44.08 billion between 2025 and 2032, according to projections from IndustryARC. Despite the wide variety of treatments currently available, many are limited by their safety profiles, long-term tolerability, and the overall effectiveness, highlighting an urgent need for new therapeutic options that are safer and more effective.

As people age, they frequently face increased difficulty in both falling and staying asleep. Changes in sleep patterns often result in a significant decrease in deep NREM sleep, which not only affects sleep quality but can also impact cognitive functions. CNYX-005 stands out due to its potential to enhance NREM sleep, which may help mitigate these age-related sleep issues.

The Journey Ahead

CNYX-005 has origins traced back to research involving Epitalon, a peptide known for its allure in longevity discussions, often touted in biohacking communities. However, the FDA has highlighted a gap in the human safety data for compounded Epitalon.

Prof. Patrick Gunning, CEO of Carnyx, emphasized the vital difference between a widely-promoted wellness compound and a thoroughly vetted therapeutic candidate like CNYX-005. The drug is currently undergoing rigorous testing to verify its safety and effectiveness through formal drug development processes.

The IND-enabling program will further investigate the drug’s safety, tolerability, pharmacokinetics, and overall exposure profile to support the eventual IND submission and the initiation of clinical trials.

About Carnyx Therapeutics

Carnyx Therapeutics is committed to developing first-in-class molecular therapeutics aimed at addressing unmet medical needs in the realms of sleep and retinitis pigmentosa. By leveraging cutting-edge biology, the company aims to advance a robust pipeline of innovative pharmacological candidates. CNYX-005, currently in the IND-enabling phase, is poised to transform the therapeutic landscape for sleep disorders, providing hope for those who struggle with achieving restful sleep.

For further information on Carnyx Therapeutics and their promising developments, visit Carnyx's website.